Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing.

Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. From our foundational discoveries in Wnt pathway modulation to unlocking the broad therapeutic potential of the CLK/DYRK target class, our focus is on the realization of new, potentially curative therapies for patients by selectively reprogramming cellular behavior.

Biosplice’s clinical pipeline is focused on osteoarthritis and oncology, with early-stage programs in neurology and other areas of significant unmet medical need.